Latest reports show that the global hormone refractory prostate cancer (HRPCA) market is expected to reach USD 18.35 billion by 2028, at a CAGR of 9.64% from 2021 to 2028. This growth is attributed to the rising prevalence of prostate cancer, increasing research and development activities, and rising demand for targeted therapies.
HRPCA is a type of prostate cancer that continues to grow despite hormone or androgen deprivation therapy. It is a recurrent stage of prostate cancer that has become resistant to hormone therapy. Hormone therapy is a common form of treatment for prostate cancer, but in some cases, the cancer can become resistant to the hormone therapy. In such cases, other treatments such as chemotherapy and immunotherapy are used.
The increasing awareness about prostate cancer and its treatments, the rising incidence of prostate cancer, and the increasing demand for targeted therapies for the treatment of prostate cancer are some of the major factors driving the growth of the global HRPCA market. In addition, the increasing focus of key players on developing novel drugs for the treatment of prostate cancer is expected to fuel the growth of the market.
However, the high cost of treatment and the lack of awareness about advanced treatments are some of the major factors restraining the growth of the global HRPCA market.
The global HRPCA market is segmented by treatment type, route of administration, end user, and region. By treatment type, the market is segmented into hormone therapy, chemotherapy, immunotherapy, and others.
By route of administration, the market is segmented into oral, intravenous, and others. By end user, the market is segmented into hospitals and cancer research centers, and others. Regionally, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The leading players operating in the global HRPCA market are Amgen, Inc., AstraZeneca, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.